Clinical trials: MN
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults
To expand the safety information regarding MN rsgp 120/HIV-1 formulated with QS21 or alum. To evaluate the immunogenicity of low doses of MN rsgp 120/HIV-1 formulated with QS21 or alum.
- Trial name
- NCT00000853
- Testing
- rgp120/HIV-1MN
- Where
- 3 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Glomerulonephritis, Membranous, Diabetic Nephropathies
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease
- Conditions
- Glomerulonephritis, Membranous, Diabetic Nephropathies, Thrombelastography, Thromboembolism
- Trial name
- NCT05656963
- Testing
- Grouping based on previous laboratory results, no intervention.
- Where
- China
- Volunteers
- 741 people
- Sponsor
- Yipeng Liu
Glomerulonephritis
A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
Membranous Nephropathy (MN) is an immune-mediated kidney disease that affects the glomerulus or the filter that removes toxins from the blood.
- Trial name
- NCT01093157
- Testing
- Adrenocorticotrophic hormone ACTH
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
Malnutrition
Exchangeable Zinc Pool Size and Zn Absorption From Sprinkles and Traditional Foods in Pakistani Infants /Toddlers
The broad objective is to improve zinc status in older infants and young children who are at risk of zinc deficiency because of combination of inadequate dietary zinc intake and high rates of diarrhea.
- Trial name
- NCT01541696
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Glomerulonephritis
A Study of Rituximab in Frontline Therapy for Glomerulonephritis
This study included patients with glomerulonephritis who planned to receive rituximab treatment, and observed the efficacy and safety of rituximab in different glomerulonephritis in the real world.
- Trial name
- NCT05761938
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
HIV Infections
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
To evaluate the safety and immunogenicity of SF-2 rgp120 vaccine in MF59 versus MN rgp120 vaccine in alum in volunteers who are seronegative for HIV-1.
- Trial name
- NCT00001031
- Testing
- rgp120/HIV-1MN, rgp120/HIV-1 SF-2
- Where
- 7 sites in United States
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Membranous Nephropathy - PLA2R Induced
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Objective: To assess the disappearance rate (half-life) of anti-PLA2R antibodies in high-risk primary membranous nephropathy (pMN) patients treated with obinutuzumab (OBI), and to evaluate immunological and clinical remission…
- Trial name
- NCT07163611
- Testing
- Obinutuzumab administration
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
HIV Infections
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
To assess the safety and immune response to two experimental vaccines when formulated with QS-21 or QS-21 plus alum. To determine whether the new preparation of QS-21 in polysorbate 80 is less reactogenic than the QS-21…
- Trial name
- NCT00001096
- Testing
- MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Membranous Nephropathy
MOR202 for Refractory MN
Membranous nephropathy (MN) - the leading cause of nephrotic syndrome (NS) in adults - is an immune-mediated disease that results from the deposition of immunoglobulins and complement components onto the sub-epithelial layer of…
- Trial name
- MONET (NCT04893096)
- Testing
- MOR202
- Where
- 2 sites in Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Commercial Sexual Exploitation
Evaluation of the Not A Number Trafficking Prevention Program in Minnesota
Although the exact scope of commercial sexual exploitation of children (CSEC) remains unknown, its significant negative physical and emotional consequences for children has been well-documented. The U.S.
- Trial name
- NCT07503912
- Testing
- Trafficking Prevention Education for Youth, Mindfulness Training
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- University of New Hampshire
Membranous Nephropathy
Obinutuzumab in Primary MN
Primary membranous nephropathy (MN) is an antibody-mediated autoimmune glomerular disease, that represents one of the most frequent causes of nephrotic syndrome in adults.
- Trial name
- ORION (NCT05050214)
- Testing
- Obinutuzumab
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Idiopathic Membranous Nephropathy
Prognostic Model of GC/TAC in the Treatment of MN
The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + tacrolimus.
- Trial name
- NCT05667896
- Testing
- glucocorticoid + tacrolimus
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
pMN, IgAN
Atacicept in Multiple Glomerular Diseases
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
- Conditions
- pMN, IgAN, Nephrotic Syndrome, MCD
- Trial name
- NCT06983028
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Vera Therapeutics, Inc.
Any Injury or Illness Acutely Impacting Work
Minnesota RETAIN Impact Evaluation
This study is a randomized control trial (RCT) to evaluate the impact of RETAIN program expansion and services on workforce retention and reduction of future workplace disability in the state of MN.
- Trial name
- NCT05146349
- Testing
- Minnesota RETAIN
- Where
- United States
- Volunteers
- 3,200 people
- Sponsor
- Mathematica Policy Research, Inc.
Preterm Birth, Very Preterm Infant
NICU-to-Home Dyadic Support for Very Preterm Infants and Families
This feasibility study will evaluate delivery of the Supporting Play Exploration and Early Development Intervention after neonatal intensive care unit discharge for very preterm infants and their families.
- Conditions
- Preterm Birth, Very Preterm Infant, Infant Development, Neonatal Intensive Care Unit
- Trial name
- MN-SPEEDI (NCT07820462)
- Testing
- Homebased SPEEDI, Telehealth SPEEDI
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
HIV Infections, HIV Seronegativity
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
The purpose of this study is to evaluate the safety and effectiveness of giving healthy volunteers a new oral HIV vaccine which has been incorporated into a bacterial cell.
- Trial name
- NCT00000868
- Testing
- Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
IgAN, LN
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
The purpose of this study was to evaluate the safety and tolerability of OMS721 (narsoplimab) in participants with Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), Membranous Nephropathy (MN), and Complement Component 3…
- Conditions
- IgAN, LN, MN, C3G
- Trial name
- NCT02682407
- Testing
- OMS721 (narsoplimab)
- Where
- 12 sites in United States, Hong Kong
- Volunteers
- 31 people
- Sponsor
- Omeros Corporation
Idiopathic Membranous Nephropathy
Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy
This pilot study is aimed at demonstrating the effectiveness of ACTH (H.P. Acthar Gel) on the lipid profile and proteinuria in participants with MN.
- Trial name
- MN (NCT00805753)
- Testing
- ACTH
- Where
- 2 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic